title: Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
authors.forename: Vuk
authors.initials: V
authors.lastname: Stambolic
authors.forename: James R
authors.initials: JR
authors.lastname: Woodgett
authors.forename: I George
authors.initials: IG
authors.lastname: Fantus
authors.forename: Kathleen I
authors.initials: KI
authors.lastname: Pritchard
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Goodwin
mesh_terms: D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin